S

Sanofi

Global pharma company; vaccines and R&D

Enterprise Data Strategy Lead

Full-TimeUpdated on 10/23/2026Deadline 11/2/26
$100.5k - $145.2k
Mid
Bachelor's, Master's
Cambridge, MA, USA+1 moreMore locations: Morristown, NJ, USA
In Person
Data & AnalyticsData Management

About the job

Requirements
  • A bachelor's degree in a quantitative discipline, data science, business administration, health informatics, epidemiology, business, life sciences, or a related field is required.
  • At least 4 years of pharmaceutical or biopharma industry experience, including significant time in Go-to-Market insights and analytics, Launch Excellence, or market access functions, is required.
  • At least 2 years in data strategy, Go-to-Market data strategy, launch readiness strategy, new product data strategy, or real-world data/real-world evidence leadership is required.
  • Familiarity with commercial and external data sources and their fit-for-purpose applications, including formulary data, sales/customer relationship management, open and closed claims (IQVIA, STATinMED, Merative), electronic health records (TriNetX), specialty pharmacy, patient/consumer data, disease registries, patient-reported outcomes, social determinants of health, and wearables, is strongly preferred.
  • Familiarity with competitive intelligence platform evaluation (AlphaSense, Clarivate, Evaluate, and Citeline), including identifying key use cases and data requirements, is strongly preferred.
  • Familiarity with launch readiness analytics and insight methodologies, including patient journey and funnel analytics, market and brand performance analysis, segmentation, forecasting, and comparative effectiveness research, is required.
  • Familiarity with data models and standards such as OHDSI OMOP and modern cloud data platforms such as Snowflake and AWS SageMaker is required.
  • Familiarity with advanced analytics and AI, machine learning, and large language model applications, including predictive modeling, natural language processing for unstructured data mining, and signal detection, is required.
  • Familiarity with SQL and/or Python and AI-assisted coding tools such as Cursor, Claude, and OpenWork, and the ability to engage technically with analytics and data engineering teams, is required.
  • Strong understanding of commercial data ecosystems and market access analytics, with familiarity with regulatory considerations for real-world evidence (FDA, EMA, ICH), is required.
  • Therapeutic-area expertise in one or more of Immunology, Rare Disease, Hematology-Oncology, Type 1 Diabetes, Transplant, or Specialty Care is strongly preferred.
  • A proven track record delivering enterprise data strategies and generating insights that drive business decisions across diverse, cross-functional stakeholder groups is preferred.
  • Experience conducting data needs assessments, gap analyses, and strategic roadmap development is preferred.
  • Demonstrated ability to translate business requirements into data-driven insights, strategic priorities, and investment decisions is preferred.
  • Demonstrated ability to lead through influence in complex, matrixed environments is preferred.
  • Strategic thinking to identify data needs, gaps, and opportunities and drive enterprise strategy to generate high-impact insights is required.
  • Ability to translate complex commercial questions into clear insights, strategic priorities, and investment decisions is required.
  • Ability to drive execution across a highly matrixed organization, set direction, enable teams, and govern quality is required.
  • Strong commercial and business acumen, with the ability to balance competing stakeholder needs across a global enterprise, is required.
  • High learning agility, intellectual curiosity, and emotional intelligence are required.
  • Commitment to scientific rigor, regulatory compliance, and ethical use of data is required.
Responsibilities
  • Define and deliver the enterprise data strategy with multi-year roadmaps that prioritize insights and analytics generation across all business functions.
  • Partner with cross-functional stakeholders in R&D, Medical Affairs, Commercial, Safety, and Brand Teams to identify, assess, and prioritize data requirements and use cases, including patient journey mapping, competitive intelligence, provider segmentation, new product forecasting, and unbranded and branded launch activities.
  • Identify and evaluate commercial and real-world data sources—including social listening platforms, specialty pharmacy, reference lab datasets, customer relationship management platforms, open and closed claims, electronic medical/health records, disease registries, and competitive intelligence platforms—for fitness for purpose.
  • Conduct enterprise-wide data and analytics assessments and gap analyses to evaluate current insight-generation capabilities against business requirements.
  • Facilitate cross-functional collaboration and investment governance, coordinating with Digital and Procurement to optimize data investments, prevent duplication, and maximize value.
  • Assess current data capabilities, conduct gap analyses, and execute the real-world data and healthcare intelligence strategy framework to define data standards that inform commercial decisions, brand performance, market access, launch readiness, medical strategy, regulatory submissions, and pipeline strategy.
  • Engage senior leaders across R&D, Commercial, Market Access, Medical Affairs, Launch Excellence, HEVA, Data Privacy/Legal, Procurement, Local Market Leads, and Digital to translate complex data needs into multi-year data roadmaps.
Desired Qualifications
  • Advanced degree.
  • Hands-on execution experience supporting analytics and data engineering teams.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...